Opko Health, Inc. (NASDAQ:OPK) has been given a $20.00 target price by stock analysts at Cantor Fitzgerald in a research report issued to clients and investors on Wednesday, October 25th. The brokerage currently has a “buy” rating on the biotechnology company’s stock. Cantor Fitzgerald’s price objective would suggest a potential upside of 264.30% from the stock’s previous close.
Other analysts have also issued research reports about the company. Zacks Investment Research raised Opko Health from a “sell” rating to a “hold” rating in a research report on Thursday, October 26th. Ladenburg Thalmann Financial Services reissued a “buy” rating and issued a $16.00 target price on shares of Opko Health in a research report on Monday, September 25th. BidaskClub raised Opko Health from a “sell” rating to a “hold” rating in a research report on Saturday, September 23rd. J P Morgan Chase & Co lowered Opko Health from an “overweight” rating to a “neutral” rating and cut their target price for the company from $12.00 to $7.00 in a research report on Thursday, September 14th. Finally, Jefferies Group LLC reissued a “hold” rating and issued a $6.50 target price (down previously from $6.80) on shares of Opko Health in a research report on Thursday, August 10th. One analyst has rated the stock with a sell rating, three have given a hold rating and six have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $13.97.
Opko Health (NASDAQ OPK) traded up $0.08 on Wednesday, reaching $5.49. The company had a trading volume of 5,745,900 shares, compared to its average volume of 4,157,070. Opko Health has a 12-month low of $5.35 and a 12-month high of $12.15. The company has a debt-to-equity ratio of 0.01, a quick ratio of 1.48 and a current ratio of 1.66.
Opko Health (NASDAQ:OPK) last released its quarterly earnings data on Wednesday, November 8th. The biotechnology company reported ($0.08) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.03). Opko Health had a negative net margin of 9.45% and a negative return on equity of 5.17%. The business had revenue of $263.50 million during the quarter, compared to analyst estimates of $319.43 million. During the same quarter in the prior year, the company posted ($0.03) earnings per share. The company’s revenue was down 11.6% on a year-over-year basis. analysts anticipate that Opko Health will post -0.2 EPS for the current year.
COPYRIGHT VIOLATION WARNING: This story was published by BBNS and is the sole property of of BBNS. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The correct version of this story can be viewed at https://baseballnewssource.com/markets/cantor-fitzgerald-analysts-give-opko-health-inc-opk-a-20-00-price-target-2/1734163.html.
In other Opko Health news, major shareholder Opko Health, Inc. bought 655,738 shares of the company’s stock in a transaction that occurred on Monday, October 30th. The shares were purchased at an average price of $3.05 per share, with a total value of $2,000,000.90. Following the completion of the acquisition, the insider now directly owns 6,678,752 shares of the company’s stock, valued at approximately $20,370,193.60. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Phillip Md Et Al Frost bought 260,000 shares of the company’s stock in a transaction that occurred on Thursday, September 14th. The stock was acquired at an average cost of $5.98 per share, for a total transaction of $1,554,800.00. Following the acquisition, the chief executive officer now directly owns 3,068,951 shares of the company’s stock, valued at $18,352,326.98. The disclosure for this purchase can be found here. Insiders have bought 1,241,038 shares of company stock worth $5,520,140 in the last ninety days. Corporate insiders own 40.19% of the company’s stock.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Credit Suisse AG boosted its stake in Opko Health by 122.0% in the first quarter. Credit Suisse AG now owns 746,958 shares of the biotechnology company’s stock valued at $5,976,000 after acquiring an additional 410,445 shares in the last quarter. State Street Corp boosted its stake in Opko Health by 40.3% in the first quarter. State Street Corp now owns 10,926,560 shares of the biotechnology company’s stock valued at $87,412,000 after acquiring an additional 3,138,685 shares in the last quarter. Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet LTD boosted its stake in Opko Health by 14.8% in the second quarter. Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet LTD now owns 135,401 shares of the biotechnology company’s stock valued at $910,000 after acquiring an additional 17,458 shares in the last quarter. State Board of Administration of Florida Retirement System boosted its stake in Opko Health by 7.5% in the second quarter. State Board of Administration of Florida Retirement System now owns 400,278 shares of the biotechnology company’s stock valued at $2,634,000 after acquiring an additional 27,940 shares in the last quarter. Finally, Paloma Partners Management Co boosted its stake in Opko Health by 70.1% in the first quarter. Paloma Partners Management Co now owns 160,970 shares of the biotechnology company’s stock valued at $1,288,000 after acquiring an additional 66,327 shares in the last quarter. Institutional investors own 22.66% of the company’s stock.
About Opko Health
OPKO Health, Inc is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations.
Receive News & Ratings for Opko Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health Inc. and related companies with our FREE daily email newsletter.